Principal Investigator: David Lynch, MD, PhD, Children’s Hospital of Philadelphia
Sponsor: Reata Pharmaceuticals
This is a multi-site, placebo-controlled study involving an Nrf-2 activator called RTA 408, which has antioxidant and anti-inflammatory properties. This study involves groups of eight participants each, and one group of at least twenty-four participants. Each of these groups take different doses of study medication or placebo. Participants are asked to complete twelve weeks of treatment with RTA 408 or placebo and to attend approximately eight visits to Children’s Hospital of Philadelphia (CHOP). This is the first study involving the testing of RTA 408 in people with Friedreich's ataxia.
For more information about this study, please contact the program at 267-426-7538 or email us at FAProgram@email.chop.edu.